This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

ZAVICEFTA® (ceftazidime-avibactam): Broad-spectrum Gram-negative coverage with consistent dosing across indications1–4

Dosing Guide

Preparation Guide

Shelf life and Storage

1. Reconstitute

Aseptically inject each vial with 10 mL
sterile water for injections (not supplied) and use immediately1.

2. Mix

Withdraw the needle and shake the vial to give a clear solution.
​​​​​​​
Insert a gas relief needle through the vial closure after the product has dissolved to relieve the internal pressure (this is important to preserve product sterility)1.

3. Dilute

Infusion bag: Further dilute the solution by transferring an appropriate volume to an infusion bag containing an infusion dilutent listed below1.
Infusion syringe: Further dilute the solution by transferring an appropriate volume, combined with sufficient volume of either sodium chloride 9 mg/mL (0.9%) or dextrose 50 mg/mL (5%) solution for injection, to an infusion syringe1.

* Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam scelerisque magna id felis scelerisque suscipit. Vestibulum sit amet turpis id ipsum sodales rutrum quis vitae elit.

1 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam scelerisque magna id felis scelerisque suscipit. Vestibulum sit amet turpis id ipsum sodales rutrum quis vitae elit.

2 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam scelerisque magna id felis scelerisque suscipit. Vestibulum sit amet turpis id ipsum sodales rutrum quis vitae elit.


                                        Steps 1 to 3 above should not exceed 30 minutes1
​​​​​​​Please refer to the full dosing table in the SmPC for more information

Peadiatric Use

Paediatric doses may be prepared in an appropriately sized infusion bag or infusion syringe. Care should be taken when calculating the volume of administration of the dose.

Please refer to the SmPC for steps to prepare for use in an infusion syringe in paediatric patients aged 3 to 12 months.


Infusion diluents1

Suitable infusion diluents for infusion bags:

  • Sodium chloride 9 mg/mL (0.9%) solution for injection
  • Dextrose 50 mg/mL (5%) solution for injection
  • Sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose)
  • ​​​​​​​Lactated Ringer’s solution

Important

  • Parenteral medicinal products should be inspected visually for particulate matter prior to administration1 
  • The compatibility of ZAVICEFTA with other medicines has not been established1 
  • ZAVICEFTA should not be mixed with or physically added to solutions containing other medicinal products1
  • Each vial is for single use only1

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

Access case studies and videos

Abbreviations

cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; ESRD, end stage renal disease; HAP, hospital-acquired pneumonia; LTO, limited treatment options; VAP, ventilator-associated pneumonia; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing.

Prescribing information
​​​​​​​Zavicefta® (ceftazidime and avibactam)
Great Britain
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion
Northern Ireland
Zavicefta®(ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

References
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–7
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76
PP-ZVA-GBR-1411. March 2022

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

Quick Links

  • Patient Risk Factors

  • Pathogen Coverage

  • AMS Resources

Ask Zavibot a Question
Paediatric Dosage
Learn more about treating Paediatric Patients

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?